Jiuzhou Pharma Pays $16 Million to Acquire US-based API CDMO

22:44 EDT 13 Sep 2019 | ChinaBio Today

Zhejiang Jiuzhou Pharma. an API company, will pay $16 million to acquire PharmAgra Labs of North Carolina, a small API CRO/CDMO business with contacts in the US and Europe. Jiuzhou makes APIs and it also provides CRO/CDMO services for APIs in China through its Rainbow Pharma division. In 2016, Jiuzhou formed a US JV with Frontage Labs to offer API and intermediate CDMO services. Earlier this month, Jiuzhou announced it would pay $110 million to acquire Novartis's Suzhou API facility and supply APIs to Novartis. More details....

Stock Symbols: (SHA: 603456) (NYSE: NVS)

Share this with colleagues:

Original Article: Jiuzhou Pharma Pays $16 Million to Acquire US-based API CDMO


More From BioPortfolio on "Jiuzhou Pharma Pays $16 Million to Acquire US-based API CDMO"

Quick Search

Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...